EDITOR: | June 4th, 2015 | 2 Comments

Promising Results from Miraculins and Amway Scout DS® Study Accepted for the 23rd World Congress of Dermatology

| June 04, 2015 | 2 Comments

Miraculins-200x125-1June 4, 2015 (Source: Marketwired) — Findings Indicate Potential for Scout DS® Technology Beyond Diabetes Screening

Miraculins Inc. (TSX VENTURE:MOM) (“Miraculins” or the “Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that the 23rd World Congress of Dermatology has accepted a scientific poster from a collaboration between Miraculins and Amway Corporation’s Open Innovation Team (“Amway”). The World Congress of Dermatology is the world’s oldest and continuous international dermatology meeting, and will be held in Vancouver, BC from June 8-13, 2015.

The poster, entitled “The Association of Skin Glycation with Facial Skin Aging”, concludes that advanced glycation end-products (“AGEs”) – as measured by the Scout DS® – are correlated with the visible signs of facial skin aging, and that vitamin supplementation was associated with lower skin AGEs. Miraculins has been reviewing these important pilot findings with Amway to determine the potential next steps in assessing the viability of Scout DS® intellectual property being utilized in a device specifically for the health and beauty segment.

The collaborative study was conducted in the United States on 555 women between the ages of 16 and 82, and was comprised of a mixed race cohort. Subjects were assessed through a cross-sectional survey using objective methods and a questionnaire that took into account age, ethnicity, BMI, smoking, sun protection habits, years working outdoors, vitamin supplementation, skin care habits, tanning, history of type 1 or 2 diabetes, kidney, heart and skin disease. Skin AGE’s were measured utilizing the Scout DS® device, and facial wrinkling and skin lightness were measured using standardized facial photography and analysis.

About Amway

Amway is a $10.8 billion direct selling business based in Ada, Michigan, USA. Top-selling brands for Amway are Nutrilite™ vitamin, mineral and dietary supplements, Artistry™ skincare and color cosmetics, and eSpring™ water treatment systems – all sold exclusively by Amway Business Owners. Global sales in 2014 made Amway the #1 direct selling business in the world, according to the Direct Selling News 2015 Global 100. For company news, visit globalnews.amway.com.

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company’s Scout DS® device has been regulatory cleared in certain markets both as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes/type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS® test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world. For more information visit www.miraculins.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, our Scout DS® studies and resulting scientific papers and discussions/collaborations with Amway Corporation and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins’ early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins’ filings with Canadian securities regulatory authorities, as well as Miraculins’ ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins’ forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statements except as may be required by law.

Scout® is a registered trademark of Miraculins Inc. All Rights Reserved. 2015.


Raj Shah has been a member of the InvestorIntel.com team for the last nearly 9 years. Recruited from Merrill Lynch, he has over 13 years’ ... <Read more about Raj Shah>

Copyright © 2022 InvestorIntel Corp. All rights reserved. More & Disclaimer »


  • The big business of age-management through skin pre-testing | InvestorIntel

    […] morning Miraculins announced they will present a peer reviewed scientific poster at the 23rd World Congress of Dermatology. The […]

    June 4, 2015 - 4:49 PM

  • Non-invasive diabetes test provides "Miraculins" results through technology | InvestorIntel

    […] Inc. (TSXV: MOM) about the Scout technology, a non-invasive diabetes test and their recent promising results as supported by the joint MIraculins and Amway Scout DS® study being accepted for the 23rd World […]

    June 12, 2015 - 10:13 AM

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.